Browsing by Author "Oguz, Arzu"

Now showing 1 - 20 of 20

Combined Versus Sequential Antracycline and Taxane Adjuvant Regimens in Triple Negative Breast Cancer Patients.
(2016) Oguz, Arzu; Keskin, Gul Sema Yildiran; Akcali, Zafer; Colak, Dilsen; Altundag, Ozden; Altundag, Mustafa Kadri; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0003-2473-4431; https://orcid.org/0000-0003-0197-6622; https://orcid.org/0000-0003-0197-6622; W-8004-2019; U-7339-2017; GRY-5456-2022; W-9219-2019; W-9219-2019
Correlation of Histopahologic Response and Prognostic Markers with Survival in Locally Advanced Non-Small Cell Lung Cancer Patients Who Have Treated with Neoadjuvant Chemotherapy
(2015) Kucukoztas, Nadire; Oguz, Arzu; Rahatli, Samed; Dizdar, Omer; Keskin, Gul Sema Yildiran; Ozyilkan, Ozgur; Altundag, Ozden; 0000-0001-8825-4918; 0000-0003-0197-6622; 0000-0001-5588-0306; 0000-0001-6512-6534; 0000-0003-3163-7429; AAD-2817-2021; W-9219-2019; AAM-3226-2021; W-8004-2019; AAJ-3047-2021
Correlation of Response and Prognostic Markers with Survival in Locally Advanced NSCLC Patients Who Have Treated with Neoadjuvant Chemotherapy
(2015) Altundag, Ozden; Kucukortas, Nadire; Rahatli, Samed; Keskin, Gul Sema Yildiran; Oguz, Arzu; 0000-0001-6512-6534; 0000-0003-3163-7429; 0000-0003-0197-6622; W-8004-2019; AAJ-3047-2021; W-9219-2019
Dosetaxel Induced Pericardial Effusion in Two Gastric Cancer Patients
(2016) Yazilitas, Dogan; Oguz, Arzu; Colak, Dilsen; Imamoglu, Goksen I.; 0000-0001-6512-6534; W-8004-2019
The Effect of Haematological Parameters on Overall Survival in Advanced Stage Non Small Cell Lung Cancer
(2014) Oguz, Arzu; Colak, Dilsen; Ersoy, Ugur; Imamoglu, Inanc G.; Altinbas, Mustafa; Unal, Dilek; Zararsiz, Gokmen
In this study, we aimed to evaluate the prognostic value of pretreatment blood count values, particularly WBC counts, in patients with advanced non-small cell lung cancer (NSCLC). The records of 186 patients with advanced stage (stage IIIB and IV) NSCLC were assessed retrospectively. Patients were divided into 3 subgroups according to WBC levels; <= 0000 /mm(3) as Group 1, >10000 and <= 15000/mm(3) as Group 2 and >15000/mm(3) as Group 3. Patient and tumor characteristics as well as outcomes in terms of overall survival (OS) were evaluated. Median OS was 13.3 months in the whole population, 25.7 months in stage IIIB and 8.9 months in stage IV patients. According to the pretreatment leukocyte values, median OS was 17.9 months in Group 1, 11.2 months in Group 2 and 8.4 months in Group 3 (p= 0.003). Median OS values in WBC groups according to stages IIIB and IV were significantly different (p< 0.001). In multivariate analyses, ECOG-PS 2 or 3, stage IV disease, anemia and high WBC levels were associated with poorer OS. In this study, higher pretreatment WBC levels were associated with poorer OS in patients with advanced stage NSCLC. Pretreatment WBC counts may represent a simple prognostic factor and may aid in tailoring treatment in patients with advanced NSCLC.
Efficacy of Trastuzumab-Based Therapy After Disease Progression on Lapatinib Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer Patients
(2014) Uncu, Dogan; Bayoglu, Ibrahim Vedat; Arslan, Ulku Yalcintas; Kucukoner, Mehmet; Artac, Mehmet; Koca, Dogan; Oguz, Arzu; Demirci, Umut; Arpaci, Erkan; Dogan, Mutlu; https://orcid.org/0000-0001-6512-6534; W-8004-2019
Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone
(2014) Rahatli, Samed; Dizdar, Omer; Kucukoztas, Nadire; Oguz, Arzu; Yalcin, Selim; Ozen, Ozlem; Reyhan, Nihan Haberal; Tarhan, Cagla; Yildiz, Ferah; Dursun, Polat; Altundag, Ozden; Ayhan, Ali
Background: Most patients with endometrial cancer have stage I disease. Adjuvant therapy in stage IB (formerly IC) endometrial cancer is controversial, treatment options including observation or brachytherapy/radiotherapy in grade 1-3 patients with or without chemotherapy. The purpose of this study was to assess the outcomes of our patients with stage IB endometrioid endometrial cancer. Materials and Methods: Sixty two patients with stage IB endometrial cancer and endometrioid histology were retrospectively evaluated. All patients were initially treated surgically by the same surgeon with comprehensive staging, i.e. total abdominal hysterectomy, bilateral salphingooopherectomy, bilateral pelvic and paraaortic lymph node dissection and omentectomy. Adjuvant radiotherapy was discussed with patients and utilized by those who accepted. Adjuvant chemotherapy was not given to any of the patients. Results: Median age was 62 (range, 42-95). Ninety percent of the patients had grade 1-2 disease. Thirteen patients (21%) received intra vaginal brachytherapy (IVBT) and one received whole pelvic radiotherapy (WPRT). Median follow-up time was 46 months (range, 9-77 months). Three patients experienced recurrence (4.8%), two of them died on follow-up and one was still alive at last visit. Two patients with recurrence had FIGO grade 2 tumors and one had a grade 3 tumor. Two patients (3.2%) died without evidence of recurrent disease. Relapse free survival at 5 years was 94.4% and overall survival was 93.1%. Conclusions: Patients with stage IB disease in our study demonstrated relatively low recurrence rates with this stage of endometrial cancer.
Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy
(2014) Oguz, Arzu; Aykas, Fatma; Unal, Dilek; Karahan, Samet; Uslu, Emine; Basak, Mustafa; Karaman, Ahmet
Background: Hepatitis B and C are the leading causes of liver diseases worldwide. For hematological and solid malignancy patients undergoing chemotherapy, increases in HBV DNA and HCV RNA levels can be detected which may result in reactivation and hepatitis-related morbidity and mortality. The aim of this study was to determine the seroprevalence of Hbs ag and Anti HCV positivity in patients with solid malignancies undergoing chemotherapy and consequences during follow-up. Materials and Methods: The files of 914 patients with solid malignancies whose hepatitis markers were determined serologically at diagnosis were reviewed retrospectively. All underwent adjuvant/palliative chemotherapy. For the cases with HBV and/or HCV positivity, HBV DNA and HCV RNA levels, liver function tests at diagnosis and during follow-up and the treatment modalities that were chosen were determined. Results: Of 914 cases, Hbs Ag, anti Hbs and anti HCV positivity were detected in 40 (4.4%), 336 (36.8%) and 26 (2.8%) of the cases respectively. All of the Hbs ag positive patients received prophylactic lamuvidine before the start of chemotherapy. In the Hbs ag and anti HCV positive cases, liver failure was not detected during chemotherapy and a delay in chemotherapy courses because of hepatitis was not encountered. Conclusions: Just as with hematological malignancies, screening for HBV and HCV should also be considered for patients with solid tumors undergoing chemotherapy. Prophylactic antiviral therapy for HBV reduces both the reactivation rates and HBV related mortality and morbidity. The clinical impact of HCV infection on patients undergoing chemotherapy is still not well characterized.
The impact of lymph node ratio on overall survival in patients with colorectal cancer
(2021) Imamoglu, Goksen İnanc; Oguz, Arzu; Cimen, Sanem; Eren, Tuelay; Karacin, Cengiz; Colak, Dilsen; Altsbas, Mustafa; Turker, Sema; Yazilita, Dogan; 34528566
Background: Lymph node metastasis is a predominant prognostic indicator in colorectal cancer. Number of lymph nodes removed surgically was demonstrated to correlate with staging accuracy and oncological outcomes. However, number of lymph nodes removed depends on uncontrolled variables. Therefore, a more reliable prognostic indicator is needed. Calculation of ratio of positive lymph nodes to total number of removed lymph nodes may be an appealing solution. Materials and Methods: We retrospectively analyzed data of 156 Stage III colorectal cancer patients whom underwent surgery between 2008 and 2015. Patients' demographic characteristics, tumor grade, location, vascular-perineural invasion status, number of removed lymph nodes, and ratio of positive lymph nodes to number of removed lymph nodes were recorded. Spearman correlation analysis was used to determine the correlation coefficient while Kaplan-Meier method and Cox proportional hazard regression model were performed for the prediction of survival and multivariate analysis, respectively. Results: Number of removed lymph nodes did not correlate with survival, but it was inversely correlated with number of positive lymph nodes. Multivariate analysis showed that ratio of removed positive lymph nodes to the total number of lymph nodes was a significant prognostic factor for survival for a ratio equal or above 0.31 was a poor prognostic indicator (108 months vs. 34 months, hazard ratio: 4.24 [95% confidence interval: 2.15-8.34]; P < 0.019). Tumor characteristics failed to demonstrate any prognostic value. Conclusions: This study showed that positive lymph node ratio (PLNR) is an important prognostic factor for Stage III colorectal cancer. Although 0.31 can be taken as threshold for "PLNR," prospective trials including larger patient groups are needed to validate its role as a prognostic indicator.
Is There Any Correlation Between Molecular Subtypes and Blood Groups in Breast Cancer?
(2014) Kucukoztas, Nadire; Oguz, Arzu; Babacan, Taner; Dizdar, Omer; Rahatli, Samed; Sarici, Saim Furkan; Keskin, Gul Sema Yildiran; Diker, Omer; Akin, Serkan; Altundag, Ozden; Altundag, Kadri; https://orcid.org/0000-0001-5588-0306; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0003-3163-7429; https://orcid.org/0000-0001-7162-4812; https://orcid.org/0000-0002-7542-9229; https://orcid.org/0000-0003-0197-6622; AAM-3226-2021; W-8004-2019; AAJ-3047-2021; GWZ-4666-2022; B-8984-2017; W-9219-2019
Morphine: Patient Knowledge and Attitudes in the Central Anatolia Part of Turkey
(2014) Colak, Dilsen; Oguz, Arzu; Yazilitas, Dogan; Immamoglu, Inanc Goksen; Altinbas, Mustafa; 24998575
Background: In Muslim majority countries (MMC) opioid use for pain management is extremely low. The underlying factors contributing to this are not well defined. Aim: The aim of this study was to survey the attitudes of cancer patients towards morphine use for pain management in a MMC and identify the factors that influence patient decisions to accept or refuse morphine as treatment for cancer pain. Settings/participants: Patients were questioned whether they had pain or not, the severity and the medications for pain management. Questions included what type of medication they thought morphine was, whether or not they would be willing to take morphine if recommended for pain management and the basis for their decision if they were against morphine use. Results: Four hundred and eighty-eight patients participated in the study. Some 50% of the patients who refused morphine use and 36.8% of the patients who would prefer another drug, if possible, identified fear of addiction as the basis for their decision. Reservation of morphine for later in their disease was the case for 22.4% of the patients who refused morphine use. Only 13.7 % of the patients refusing morphine and 9.7% of the patients who preferred another drug, if possible, cited religious reasons as the basis for this decision. Conclusions: Identifying the underlying factors contributing to low opioid use for pain management in MMC is important. Once the underlying factors were identified, all efforts should be taken to overcome them as they are barriers to improving patient pain management.
Paraaortic Lymph Node Dissection in Endometrial Cancer; Is It Necessary?
(2014) Dizdar, Omer; Oguz, Arzu; Kucukoztas, Nadire; Dursun, Polat; Altundag, Ozden; Ayhan, Ali
RECURRENCE AND THE SURVIVAL ANALYSIS OF LIVER TRANSPLANTED HEPATOCELLULAR CARCINOMA PATIENTS
(2020) Rahatli, Samed; Oguz, Arzu; Altundag, Ozden; Soy, Ebru H. Ayvazoglu; Haberal, Mehmet A.
Response Rates of Taxane Rechallenge in Metastatic Breast Cancer Patients Previously Treated with Adjuvant Taxanes
(2016) Kucukoztas, Nadire; Oguz, Arzu; Rahatli, Samed; Altundag, Ozden; Altundag, Kadri; 0000-0003-0197-6622; 0000-0001-5588-0306; 0000-0003-3163-7429; 0000-0001-6512-6534; 27837607; W-9219-2019; AAM-3226-2021; AAJ-3047-2021; W-8004-2019
Purpose: This study was conducted to determine the efficacy of taxane-based regimens in patients with metastatic breast cancer pre-treated with taxanes in adjuvant treatment and also to assess the response rates of taxanes in each treatment line. Methods: The data of 939 breast cancer patients, who had received adjuvant taxane-based chemotherapy, were reviewed retrospectively. In 191 of them local/distant recurrences were detected. The treatments that were given when metastases occurred and the responses were recorded. Response rates (RRs), clinical benefit rates/CBR (complete response/CR + partial response/PR + stable disease/SD) and progression-free (PFS) and overall survival (OS) values were determined. RRs to the most frequently used protocols in our institutes (capecitabine-based and taxane-based regimens) were compared. Results: Of 191 patients, 11 didn't receive treatment and for the remaining 180 patients 45 (24%) received taxane-based therapies, 89 (49.4%) received capecitabine-based therapies, 28 (15.6%) received hormonotherapy and 18 (10%) received other chemotherapeutics. The RR for first-line taxane regimen was 58.5%, consisting of 5 CRs (12%) and 19 PRs (46%). Menopausal status, histological grade, estrogen/progesterone receptors, cerbB2 status, having PFS > ors 2 years and the site of metastases did not predict response to first-line taxane treatment. For the 2nd and 3rd or later line therapies, RRs of taxane rechallenge were above 40%. Conclusion: Rechallenging with taxanes after (neo)adjuvant taxane exposure seems to be a reasonable option even in 3rd or further line treatments with high response rates.
Response Rates of Taxane Rechallenge in Metastatic Breast Cancer Patients, Previously Treated with Adjuvant Taxanes
(2014) Oguz, Arzu; Babacan, Taner; Dizdar, Omer; Kucukoztas, Nadire; Rahatli, Samed; Keskin, Gul Sema Yildiran; Altundag, Ozden; Altundag, Kadri; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0001-5588-0306; https://orcid.org/0000-0003-3163-7429; https://orcid.org/0000-0003-0197-6622; W-8004-2019; AAM-3226-2021; AAJ-3047-2021; W-9219-2019
The Role of Selvester Score on 12-Lead ECG in Determination of Left Ventricular Systolic Dysfunction Among Patients Receiving Trastuzumab Therapy
(2019) Ciftci, Orcun; Yilmaz, Kerem Can; Karacaglar, Emir; Akgun, Arzu Neslihan; Yilmaz, Mustafa; Oguz, Arzu; Muderrisoglu, Ibrahim Haldun; 0000-0001-8926-9142; 0000-0001-6512-6534; W-5233-2018; W-8004-2019; ABI-6723-2020
Objective: Breast cancer is the most common cancer in women. Trastuzumab is an effective breast cancer agent. The most significant side effect of trastuzumab is left ventricular systolic dysfunction. Selvester score calculated from 12-lead electrocardiography (ECG) has a proven accuracy in predicting left ventricular infarct area and scar volume. We aimed to determine its role in detection of left ventricular systolic dysfunction among trastuzumab-treated breast cancer patients. Methods: A total of 60 trastuzumab-treated patients were retrospectively included. The patients were grouped into two groups with trastuzumab-induced left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) <55%) (Group 1) and without (Group 2). The left ventricular systolic dysfunction group was divided into two subgroups: LVEF <50% and (Group 1a) and LVEF 50-54% (Group 1b). The Selvester score was compared between Group 1 and Group 2, and between Group 1a, Group 1b, and Group 2. The predictive role of Selvester score in trastuzumab-induced left ventricular systolic dysfunction was determined with univariate and multivariate analysis. Results: The mean age of the patients was 56.7 +/- 13.7 years. Twenty (21.1%) patients had trastuzumab-induced left ventricular systolic dysfunction. The Selvester score was similar between Group 1 and Group 2. Group 1a had a significantly greater Selvester score compared to Group 1b and Group 2 (p<0.05); however, Group 1b and Group 2 had similar Selvester scores (p>0.05). The Selvester score was significantly correlated with left ventricular systolic dysfunction in univariate analysis (r=0.189, p<0.05) but not in multivariate analysis. Conclusion: Selvester score may be useful especially for detecting severe trastuzumab-induced left ventricular systolic dysfunction.
Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant
(2020) Rahatli, Samed; Soy, Ebru H. Ayvazoglu; Oguz, Arzu; Altundag, Ozden; Moray, Gokhan; Haberal, Mehmet; 0000-0003-0197-6622; 0000-0002-3462-7632; 0000-0003-2498-7287; 0000-0003-3163-7429; 0000-0001-6512-6534; 0000-0002-0993-9917; 32279656; W-9219-2019; AAJ-8097-2021; AAE-1041-2021; AAJ-3047-2021; W-8004-2019; AAC-5566-2019
Objectives: Hepatocellular carcinoma remains a major health problem with increased rates of mortality. The curative treatment options are resection or liver transplant. Because the Milan criteria are restrictive for candidates, they have been expanded into alternative sets of criteria. We aimed to evaluate our indications for liver transplant and their results for hepatocellular carcinoma. Materials and Methods: Between December 1988 and January 2020, we performed 652 liver transplant procedures (443 living donors, 209 deceased donors) at Baskent University (Ankara, Turkey). At Baskent University, we developed liver transplant criteria for patients with hepatocellular carcinoma. For our criteria, liver transplant for hepatocellular carcinoma was performed in patients without major vascular invasion and distant metastasis. Clinical data on cancer demographics, recurrence patterns, and survival outcomes were evaluated retrospectively. Results: Of 652 total patients, 49 adult patients (8%) with diagnosis of hepatocellular carcinoma were included in this study. Median age was 55 years. Hepatocellular carcinoma recurrence after liver transplant was detected in 13 patients. Median overall survival was 64.3 months for all study patients; however, median survival was significantly lower in patients who had recurrence (126.3 vs 43.4 mo for nonrecurrent vs recurrent groups; P = .024). In the expanded criteria group (n = 25), 7 patients (28%) had hepatocellular carcinoma recurrence during follow-up, whereas this ratio was 25% (6/24 patients) in the Milan criteria group, with median time to recurrence of 12.6 versus 11.7 months, respectively (not significantly different). Conclusions: Multidisciplinary treatment modalities, including surgery, interventional radiology techniques, and medical treatments, will probably lead to prolonged survival in patients with hepatocellular carcinoma. According to our center's expanded criteria, recurrence rates and time to recurrence were similar to those shown with the Milan group. We showed that Milan criteria can be safely expanded with promising results even in patients beyond Milan criteria.
Trastuzumab in Metastatic Breast Cancer After Complete Remission: How Long is Enough?
(2015) Oguz, Arzu; Rahatli, Samed; Altundag, Ozden; Altundag, Kadri; 0000-0003-3163-7429; 0000-0003-0197-6622; 0000-0001-6512-6534; 26123599; AAJ-3047-2021; W-9219-2019; W-8004-2019
Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer
(2016) Oguz, Arzu; Keskin, Gul Sema; Colak, Dilsen; Altundag, Ozden; Akcali, Zafer; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0003-0197-6622; https://orcid.org/0000-0003-2473-4431; 26644534; W-8004-2019; GRY-5456-2022; GRY-5456-2022; W-9219-2019; U-7339-2017
Two Cases of Sarcomas in the Heart; One Primary, One Metastatic
(2015) Keskin, Gul Sema Yildiran; Oguz, Arzu; Rahatli, Samed; Akcali, Zafer; Altundag, Ozden; 0000-0003-0197-6622; 0000-0001-6512-6534; 0000-0003-2473-4431; 0000-0003-3163-7429; W-9219-2019; W-8004-2019; U-7339-2017; AAJ-3047-2021